STOCK TITAN
  1. Home
  2. News
  3. ARDX

Ardelyx Inc - ARDX STOCK NEWS

Welcome to our dedicated news page for Ardelyx (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.

News
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Rhea-AI Summary
Ardelyx, Inc. (ARDX) will report its First Quarter 2024 Financial Results on May 2, 2024, and hold a conference call at 4:30 p.m. Eastern Time to discuss financial performance and business updates. Investors can join the call by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) or access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences earnings
-
News
Ardelyx, Inc. Reports Employment Inducement Grants
Rhea-AI Summary
Ardelyx, Inc. (ARDX) announced the grant of stock options and RSUs to its new Executive Vice President and non-executive employees. The stock options and RSUs were granted as inducements material to their employment, with a 4-year vesting period. Each stock option has an exercise price of $7.70 per share and a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
Rhea-AI Summary
Ardelyx, Inc. appoints Mike Kelliher as Executive VP, Corporate Development and Strategy. Mr. Kelliher brings over 20 years of biopharmaceutical industry experience, focusing on mergers, acquisitions, business development, and operational leadership. His expertise aims to drive Ardelyx's growth following successful product launches. The company sees this appointment as pivotal for its future success and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Ardelyx, Inc. Reports Employment Inducement Grants
Rhea-AI Summary
Ardelyx, Inc. granted new non-executive employees stock options and RSUs as inducements for employment, with specific terms and conditions. The options have an exercise price of $8.69 per share, while the RSUs vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and the company's Employment Commencement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
News
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Ardelyx, Inc. announced that Susan Rodriguez, chief commercial officer, will participate in a Cardiorenal panel discussion at the Cowen 44th Annual Health Care Conference. The event will take place on March 5, 2024, at 10:30 A.M. Eastern Time in Boston, MA. The live webcast will be accessible on the Ardelyx website, with a replay available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences
-
News
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Ardelyx, Inc. reports strong commercial performance in FY 2023 with $80.1 million in net product sales revenue for IBSRELA and $2.5 million for XPHOZAH. The company ends FY 2023 with $184.3 million in cash and investments. Expectations for 2024 net product sales revenue are between $140.0 to $150.0 million. Key developments include expansion of IBSRELA sales team, initiation of a real-world evidence study for XPHOZAH, and release of the 2023 ESG report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
earnings
News
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on February 22, 2024, to discuss fourth quarter and full year 2023 financial results and provide a business update. Participants can join by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international) and asking to be joined into the Ardelyx call. The live audio of the conference call will be webcast and available for replay for 30 days on the company's website at www.ardelyx.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
conferences earnings
-
News
Ardelyx, Inc. Reports Employment Inducement Grants
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) granted new non-executive employees options to purchase 23,580 shares of the company's common stock and 33,300 Restricted Stock Units (RSUs) on January 10, 2024. Each stock option has an exercise price of $9.08 per share, with vesting over four years. The RSUs also vest over four years, with 25% vesting on the first anniversary of the employee's first day of employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
none
-
News
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) achieved significant commercial progress in 2023, with IBSRELA® expected to generate over $1.0 billion in annual U.S. net product sales revenue at peak. The company also saw a strong initial response to XPHOZAH® and finished 2023 with strong revenue performance, expecting IBSRELA to achieve greater than ten percent market share at peak. The company also had total cash, cash equivalents, and short-term investments of approximately $184 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.79%
Tags
none
News
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) to Host Live Event and Webcast for IBSRELA® (tenapanor) Management Update and Key Opinion Leader Discussion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
Stock ARDX logo
Ardelyx Inc

Nasdaq:ARDX

ARDX Rankings

#2122 Ranked by Market Cap
#88 Ranked by Stock Gains
N/A Ranked by Dividends

ARDX Stock Data

1.56B
226.69M
1.95%
60.33%
15.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fremont

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.